Free Newsletter
Medco plots bigger push into research
If Medco Health Solutions gets its way, we'll all start using pharmaceuticals more effectively. And in a bid to push us to do just that, it's sponsoring more research to help improve drug therapy.
Medco took it upon itself to study whether heartburn drugs interfered with the effectiveness of the widely used clot-buster Plavix, co-marketed by Bristol-Myers Squibb and Sanofi-Aventis. Released in 2008, the research suggested they did. The company went on to sponsor 12 studies that were published or presented last year, CEO David Snow Jr. said during his fourth-quarter earnings call.
The company is so committed to the idea of sponsoring studies, that it has created a new research institute. By scientifically exploring ways that genetic testing can better target drug use--and looking at which drugs are most effective for various diseases--Medco is hoping to "improve outcomes and reduce costs," Snow said (as quoted by the Wall Street Journal Health Blog). Hard to argue with that.
- check out the Medco release
- read the Health Blog post
Related Articles:
Plavix vs. Effient shows payer power
More generics, more frugal clients for Medco
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: